Amedisys Announces Clinical Excellence in Speech Language Pathology
March 31 2016 - 11:00AM
Amedisys, Inc. (NASDAQ:AMED) today announced for the fifth year in
a row it has proven clinical excellence with its Speech-Language
Pathology (SLP) program as evidenced by the American
Speech-Language and Hearing Association (ASHA) National Outcomes
Measurement System (NOMS) report for 2015.
NOMS is a data collection system developed to illustrate the
value of Speech-Language Pathology services provided to patients
with swallowing deficits, cognitive and memory impairments, and
communication disorders. It is a recognized outcome data collection
system that is recognized by the Centers for Medicare and Medicaid
Services (CMS).
The key to NOMS is the use of ASHA's Functional Communication
Measures (FCMs). FCMs are a series of disorder specific seven-point
rating scales designed to describe the change in an individual's
functional communication, swallowing, or cognitive/memory abilities
over the course of treatment.
The 2015 data reflects the Amedisys Speech-Language Pathology
program exceeded the national industry average by 12.3% compared to
the healthcare industry for 2015. The national average for 2015 was
51.6% of treatment goals met in the home, while Amedisys met 63.9%
of treatment goals.
“We are extremely proud of our more than 400 Speech-Language
Pathologists here at Amedisys for achieving this level of high
quality care for our patients,” said Dr. David Hutchings,
CCC-SLP.D., the Senior Managing Director of Rehabilitation for
Amedisys. “Helping our patients recover their ability to swallow,
remove feeding tubes, and to improve communication and memory
deficits is extremely rewarding.”
Each year approximately 15 million are diagnosed with swallowing
disorders (Dysphagia) causing more than 60,000 deaths.
Conditions that impact a person’s ability to swallow, communicate
or cognitive/memory abilities often include stroke, COPD, dementia,
Alzheimer’s, Multiple Sclerosis, ALS, and Parkinson’s.
Amedisys’ Speech-Language Pathology program has proven clinical
outcomes which include reduced risk of aspiration pneumonia;
increased ability to eat and swallow; reduced need for feeding
tubes; increased weight and nutrition status; improved ability to
communicate wants and needs; and enhanced memory and cognitive
functions or learned compensation techniques.
For more information about NOMS, please visit:
http://www.asha.org/members/research/noms/.
For more information about the Amedisys Speech-Language
Pathology program, please visit: www.Amedisys.com/SLP.
About Amedisys:Amedisys, Inc. is a leading
healthcare at home Company delivering personalized home health and
hospice care. Amedisys is focused on delivering the care that is
best for our patients, whether that is home-based recovery and
rehabilitation after an operation or injury, care focused on
empowering them to manage a chronic disease, or hospice care at the
end of life. More than 2,200 hospitals and 61,900 physicians
nationwide have chosen Amedisys as a partner in post-acute care.
Founded in 1982, headquartered in Baton Rouge, LA with an executive
office in Nashville, TN, Amedisys is a publicly held company. With
more than 13,000 employees, in 411 care centers
in 34 states, Amedisys is dedicated to delivering
the highest quality of care to the doorsteps
of 360,000 patients in need every year. For more
information about the Company, please visit: www.amedisys.com.
Contact:
Kendra Kimmons
Managing Director of Communications
225-299-3708
kendra.kimmons@amedisys.com
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Apr 2023 to Apr 2024